Patients & Visitors ›

Profile

Profile
Research

Allison Brashear, M.D.

Professor, Neurology
Women's Health Center of Excellence for Research, Leadership, Education

Clinical Specialties

Movement Disorders, Neuromuscular Diseases, Botulinum Toxin

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-716-4101
Department: 336-716-4101

Media Medical Expert »

Education & Training

B.A., Depauw University , 1983
M.D., Indiana University School of Medicine , 1987
Internship, Medicine, Indiana Univ Med Ctr & Hosps, 1988
Residency, Neurology, Indiana Univ Med Ctr & Hosps, 1991

Board Certifications

American Board of Psychiatry & Neurology, Neurology

Memberships

American Academy Of Neurology

NPI Number

1881673713

Allison Brashear, M.D.

Professor, Neurology Women's Health Center of Excellence for Research, Leadership, Education

Research Interests

health services, research/outc, neurosciences/behavior

Contact Information

Academic: 336-716-3545 | Department: 336-716-4101

Media Medical Expert »

Recent Publications

Brashear A, Cook J, Amponsah A, Hill D, Snively B, Light L, Suerken C, McCall WV, Boggs N, Stacy M, Ozelius L, Sweadner K. Psychiatric and neurocognitive morbidity in rapid-onset dystonia Parkinsonism [abstract]. Neurology. 2012;78(Suppl 1):P01.225.

Brashear A, Ozelius LJ, Sweadner KJ.Rapid-onset dystonia-Parkinsonism: more than just dystonia

Ghetti B, Brashear A, Hagen M, Sweadner K. Rapid onset dystonia-Parkinsonism associated with the I758S ATP1A3 mutation: a neuropathologic study of two affected siblings [abstract]. J Neuropathol Exp Neurol. 2012;71(6):592-593.

Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism Relat Disord. 2012;18(6):737-741.

Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R. 2012;4(1):4-10.

Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S. Patient registry of outcomes in spasticity care. Am J Phys Med Rehabil. 2012;91(9):729-746.

Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology. 2012;79(11):1168-1173.

Charles D, Brashear A, Hauser RA, Li H-I, Boo L-M, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35(5):208-214.

Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012;54(11):1065-1067.

Brashear A, Elovic E, eds. In: Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: .

Brashear A, Elovic E. Why is spasticity important? In: Brashear A, Elovic E, eds. Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: 3-4.

Brashear A. Botulinum toxin in the treatment of upper limb spasticity In: Brashear A, Elovic E, eds. Spasticity: diagnosis and management. New York: Demos Medical Publishing;2011: 131-140.

Chen R, Brashear A. A diagnostic test to distinguish psychogenic dystonia from organic dystonia? [editorial]. Neurology. 2011;76(7):590-591.

Brashear A, Hill DF, Boggs N, Ozelius L, Sweadner KJ, Light L, Stacy M, Snively BM, McCall WV. Psychosis: part of the rapid-onset dystonia-Parkinsonism (RDP) phenotype? [abstract]. Neurology. 2011;76(9 Suppl 4):A640.

Evidente VGH, Fernandez HH, LeDoux MS, Brashear A, Marx MW, Grafe SK, Comella CL. Flexible dosing with incobotulinumtoxin-A (Xeomin); botulinum neurotoxin type-A, free from accessory proteins) in cervical dystonia [abstract]. Eur J Neurol. 2011;18(Suppl 2):511.

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-323.

Brashear A, Hill D, Snively BM, Sweadner KJ, Ozelius L. De novo and recurrent mutations in ATP1A3 are common in rapid-onset dystonia-Parkinsonism [abstract]. Neurology. 2010;74(9 Suppl 2):A204.

Yablon SA, Simpson D, Gracies JM, Barbano R, Brashear A. Tizanidine improves geriatric depression scale scores in stroke and brain injury survivors with spastic hemiparesis: post-hoc analysis from a randomized, double-blind, placebo-controlled trial [abstract]. Neurology. 2010;74(9 Suppl 2):A409-A410.

Brashear A, Hill DF, Snively B, Sweadner KJ, Ozelius L. Now triggers in rapid-onset dystonia-Parkinsonism (RDP) [abstract]. Neurology. 2010;74(9 Suppl 2):A205.

Brashear A. Botulinum toxin type A: exploring new indications. Drugs Today (Barc). 2010;46(9):671-682.

Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380-385.

Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11(3):153-161.

Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009;3():1-7.

Sacino A, Hampton TG, Lingrel JB, Brashear A, Sweadner KJ. Rapid onset dystonia-parkinsonism: symptoms in a mouse deficient in Na,K-ATPase alpha3 [abstract]. Mov Disord. 2009;24(Suppl 1):S112-S113.

Gracies J-M, Yablon S, Raghavan P, Barbano R, Brashear A, Simpson D. Relationship between active function and tone in a placebo-controlled study of botulinum neurotoxin vs tizanidine in upper limb spasticity [abstract]. Arch Phys Med Rehabil. 2009;90(10):e5-e6.

Barbano RL, Ozelius L, Hill DF, Brashear A. Variable phenotypic expression of rapid onset dystonia parkinsonism in a newly discovered Italian family with a T613M mutation in the ATP1A3 gene [abstract]. In: Abstracts of the 61st Annual Meeting of the American Academy of Neurology; 2009 April 25 - May 2; Seattle (WA). 2009;():IN2-1.003.

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-1706.

Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008;89(5):799-806.

Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14(5):289-298.

Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJM, Gollamudi S, Green A, Guimaraes J, Haake B, Klein C, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain. 2007;130(Pt 3):828-835.

Yablon SA, Brashear A, Gordon MF, Elovic DP, Turkel CC, Daggett S, Liu J, Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007;29(4):683-690.

Brashear A, Farmer D, Wood F, Bressman SB, Dobyns WB, Ozelius LO. ATP1A3 mutations in rapid-onset dystonia Parkinsonism: is there more to the story? [abstract]. Ann Neurol. 2006;60(Suppl 10):S11.

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67(12):2233-2235.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

WFBMC
All

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Neurology

Clinical Specialties

Movement Disorders, Neuromuscular Diseases, Botulinum Toxin

Quick Reference

Request an Appointment

New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.

Find a Doctor Ways to Give

Spotlight

New Hope for the Treatment of Upper Limb Spasticity

Upper limb spasticity, the tightening and stiffening of wrist, elbow and finger muscles, can occur weeks, months or years after a stroke. Learn more about the symptoms of upper limb spasticity and new treatment options to help patients live better and more active lives.